Hyperthyroidism Treatment Market and Drugs

Hypoparathyroidism is a rare endocrine condition marked by low-calcium and high-phosphate levels as compared to a normally lower or inappropriate level of normal Parathyroid hormone (PTH).

Understanding of the Hypoparathyroidism epidemiological data become difficult, considering that the country-specific data is limited.

According to the review of literature, the hypoparathyroidism prevalence of in the United States was reported 37 per 100,000 person-years. Out of which, 72% of cases belongs to females. (Clarke et al.)

Only a few studies exist on the epidemiology of Hypoparathyroidism in Europe (in Denmark, Netherlands, and Hungary).

The most frequent etiology is surgical removal or loss of viability of parathyroid glands.

Hypoparathyroidism Treatment

The goals of optimal hypoparathyroidism treatment include maintaining serum calcium within the low-normal range, and serum phosphate and magnesium levels within the normal range. Standard Hypoparathyroidism treatment includes calcium supplements and activated vitamin D, namely calcitriol or alfacalcidol. Vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol) supplements, magnesium, and thiazide diuretics, which are used as per the requirement.

Hypoparathyroidism continued to be one of the last endocrine disorders without available hormone replacement therapy until the approval of rhPTH therapy, which offered a more physiologic approach to the treatment of hypoparathyroidism in cases where other conventional treatment options failed.

There are a number of activated vitamin D analogues available for the treatment of Hypoparathyroidism such as calcitriol in the US and in Europe alfacalcidol (1α-hydroxyvitamin D) and dihydrotachysterol are available.

Companies worldwide are diligently working towards the development of novel Hypoparathyroidism therapies.

Hypoparathyroidism Drugs

Major Pharma players, such as Entera Bio, Ascendis Pharma, and others are involved in developing therapies for the disease.

The entry of new therapies by these companies is expected to fuel Hypoparathyroidism market growth.

PTH (1-34) (Entera Bio), TransCon PTH (Ascendis Pharma) along with others are in the various stages of development for the treatment of Hypoparathyroidism. Additionally, hormonal replacement therapies, some of the companies are also developing dietary supplements, such as Amorphous Calcium (Amorphical Ltd.).